Intervention not reported
Mortality, all‐cause · patients with HIV infection or exposure
The intervention showed no clear difference in mortality, all‐cause (low certainty).
1 finding from 1 review
Intervention not reported
Mortality, all‐cause · patients with HIV infection or exposure
The intervention probably leads to lower mortality, all‐cause (moderate certainty).
1 finding from 1 review
Intervention not reported
Mortality, all‐cause · patients with HIV exposure (children)
1 finding from 1 review
Intervention not reported
Mortality, all‐cause · patients with diarrhoea in children with HIV infection
The intervention may leads to lower mortality, all‐cause (low certainty).
1 finding from 1 review
All‐cause mortality by day 60 · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
Bamlanivimab showed no clear difference in all‐cause mortality by day 60 compared with placebo (low certainty).
1 finding from 1 review
All‐cause mortality by day 30 · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
Casirivimab/imdevimab showed no clear difference in all‐cause mortality by day 30 compared with placebo (low certainty).
1 finding from 1 review
All‐cause mortality within 6 months · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
1 finding from 1 review
All‐cause mortality within 6 monthsb · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
Tixagevimab/cilgavimab showed no clear difference in all‐cause mortality within 6 monthsb compared with placebo (low certainty).
1 finding from 1 review